RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future is a research paper published in Drugs (2024). On theSindex it has a DataRank of 0. It has been cited 17 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Center
Grant: R01CA251591
National Cancer Center
Grant: R01CA273224-01
National Cancer Center
Grant: P30CA008748
National Cancer Center
Grant: T32-CA009207
American Society of Clinical Oncology
Grant: ASCO Young Investigator Award
National Institutes of Health
Grant: 5T32CA009207-43
Investigational Cancer Therapeutics Training Program
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5R01CA273224-03
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
National Institutes of Health
Grant: 5R01CA251591-02
Predicting sensitivity and resistance in RET-driven cancers
Fields of Study
Keywords